Study characteristics and baseline demographic characteristics of patients with hip fracture who received a direct oral anticoagulant before or after implementation of a vitamin K antagonist–reversal protocol, and of patients who did not receive an anticoagulant (control)
| Study | Study design | Inclusion criteria | Reversal protocol | No. of patients | Age, mean ± SD (range), yr | Female sex, no. of patients | |||
|---|---|---|---|---|---|---|---|---|---|
| Control | DOAC | Control | DOAC | Control | DOAC | ||||
| Schermann et al.,20 2019 | |||||||||
| CRIF | Retrospective cohort | Proximal hip fracture | 24–36 h delay: rivaroxaban, apixaban; 12–24 h delay: dabigatran | 977 | 60 | 82.7 ± 8 | 86.1 ± 5.7 | 762 | 44 |
| HA | Retrospective cohort | Proximal hip fracture | 24–36 h delay: rivaroxaban, apixaban; 12–24 h delay: dabigatran | 489 | 29 | 82.8 ± 7.6 | 86.2 ± 7.1 | 335 | 16 |
| Schuetze et al.,29 2019 | Retrospective cohort | Inter- or subtrochanteric hip fracture | Surgery within 24 h of admission, no reversal | 146 | 52 | NR | NR | NR | NR |
| Franklin et al.,14 2018 | Retrospective cohort | Hip fracture, 60–89 yr of age | Surgery within 48 h of admission, no reversal | 76 | 19 | NR | NR | 32 | 8 |
| Mullins et al.,27 2018 | Retrospective cohort | Hip fracture | No time delay to surgery, no reversal | 62 | 63 | 85 (66–100) | NR | NR | 47 |
| Weighted total, no. (%) | NA | NA | NA | 1750 | 223 | 82.8 | 86.1 | 1542 (73.2) | 171 (67.3) |
CRIF = closed reduction internal fixation; DOAC = direct oral anticoagulant; HA = hemiarthroplasty; NA = not available; NR = not recorded; SD = standard deviation.